These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3266156)

  • 1. Lymphocyte function tests in cirrhotic patients under treatment with spironolactone and potassium canrenoate.
    Cuppone R; Del Vecchio S; Zanninelli G; Delle Monache M; Ulissi A; Tavanti A; Angeloni A; Ricci GL
    J Int Med Res; 1988; 16(6):436-42. PubMed ID: 3266156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
    Dupont A
    Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716
    [No Abstract]   [Full Text] [Related]  

  • 5. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.
    Francavilla A; Di Leo A; Eagon PK; Polimeno L; Guglielmi F; Fanizza G; Barone M; Starzl TE
    Gastroenterology; 1987 Oct; 93(4):681-6. PubMed ID: 3623016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gynaecomastia after spironolactone and potassium canrenoate.
    Bellati G; Idéo G
    Lancet; 1986 Mar; 1(8481):626. PubMed ID: 2869341
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of diuretics in preventing ascites recurrence.
    Arrigoni A; Andriulli A; Gindro T; Verme G
    Br J Clin Pract; 1988 Mar; 42(3):116-20. PubMed ID: 3207572
    [No Abstract]   [Full Text] [Related]  

  • 10. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone and canrenoate: different antialdosteronic diuretic agents.
    Gentilini P
    Hepatology; 1991 May; 13(5):999-1000. PubMed ID: 2030004
    [No Abstract]   [Full Text] [Related]  

  • 12. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic activity of potassium canrenoate in man.
    Yeh BK; Chiang BN; Sung PK
    Am Heart J; 1976 Sep; 92(3):308-14. PubMed ID: 949026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone and potassium canrenoate metabolism.
    Gardiner P
    Lancet; 1985 Dec 21-28; 2(8469-70):1432. PubMed ID: 2867429
    [No Abstract]   [Full Text] [Related]  

  • 15. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
    Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
    Dasgupta A; Johnson MJ; Sengupta TK
    J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.
    Cook CS; Hauswald CL; Schoenhard GL; Piper CE; Patel A; Radzialowski FM; Hribar JD; Aksamit W; Finnegan P; Bible RH
    Arch Toxicol; 1988 Jan; 61(3):201-12. PubMed ID: 3355365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.